Max Hodak, a former leader at Neuralink, is making waves in the tech world with his new venture, Science Corporeal. The startup’s flagship project, dubbed “Science Eye,” aims to transform the treatment of blindness while also enhancing the realms of virtual and augmented reality.

In an exclusive chat with Futurism, Hodak unveiled the innovative features of Science Eye, which integrates gene therapy with advanced microLED technology to potentially restore sight for those affected by vision impairment. Early trials conducted on rabbits have yielded encouraging results, with human trials anticipated to initiate in about eighteen months.

Hodak imagines a future where experiencing fully immersive virtual worlds doesn’t necessitate complex surgical procedures. Through their cutting-edge technology, Science Corporeal seeks to redefine the boundaries of traditional VR headsets and offer users a remarkably intuitive AR/VR experience.

While some may liken Science Corporeal to Neuralink, the startup distinguishes itself through a novel technical methodology and a commitment to steady, sustainable progress. With a robust $160 million in funding, it is poised to emerge as a significant contender in the brain-computer interface landscape.

As it looks to the future, Science Corporeal is focused on delivering its innovative solutions to patients while expanding its ambitions beyond mere visual aids. The company’s meticulous and pragmatic strategy sets it apart in the fast-paced field of neurotechnology.

With Science Corporeal’s ongoing innovations, the potential to enhance human experiences through sophisticated technology seems limitless. Keep an eye out for this trailblazing startup and the exciting developments ahead.